Dr. William Ince

Dr. William Ince is a dedicated Consultant Clinical Oncologist who provides comprehensive, patient-centred care across a broad range of oncological conditions. He specialises in the non-surgical management of urological malignancies, including prostate, kidney, and bladder cancers, as well as head and neck cancers and non-melanoma skin cancers. Dr. Ince incorporates advanced treatment strategies to formulate individualised care plans tailored to each patient's specific diagnosis, combining evidence-based medicine with an empathetic, supportive approach to guide individuals through every stage of their care.

Dr. Ince earned his medical degree from the University of London in 2009. He completed extensive postgraduate specialist training in Oncology across London, Cambridge, and Norwich, receiving several undergraduate and postgraduate distinctions, including the prestigious Royal College Gold Medal for achieving the highest score in his fellowship examination. Prior to focusing on specialist oncology, he worked as a General Practitioner, gaining valuable clinical experience across primary, secondary, and tertiary healthcare settings. Dr. Ince holds professional qualifications with the Royal College of Radiologists (FRCR), the Royal College of Physicians (MRCP), and the Royal College of General Practitioners (MRCGP). He is also an active member of both the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO).

In addition to his clinical responsibilities, Dr. Ince is actively involved in clinical research and academic advancement. He serves as a Principal Investigator and Chief Investigator for numerous national and international clinical trials evaluating innovative systemic therapies, tumour biomarkers, and targeted treatments. His primary clinical interests encompass cutting-edge options such as immunotherapy, targeted therapies, chemotherapy, and advanced radiation techniques including stereotactic body radiotherapy (SBRT/SABR). Dr. Ince also contributes to national cancer research working groups and collaborates with patient support organisations to co-author clear, informative guidance for patients and their families.